Serum High-Sensitivity C-Reactive Protein (HS-CRP) Levels as a Prognostic Biomarker in Pregnant Women with Preeclampsia: A Comparative Prospective Cohort Study (Code-T0178)
Keywords:
Preeclampsia, HS-CRP, prognostic biomarker, inflammation, adverse outcomes, maternal health.Synopsis
Introduction: Preeclampsia, a hypertensive disorder in pregnancy, significantly contributes to maternal and perinatal morbidity. Its pathogenesis involves endothelial dysfunction and inflammation, with high-sensitivity C-reactive protein (HS-CRP) emerging as a marker of systemic inflammation. This study investigates HS-CRP levels as a prognostic biomarker for adverse fetomaternal outcomes in preeclampsia.
Aims and Objectives:
Primary Objective:
To estimate and compare serumHigh Sensitive-C-Reactive Protein levelsinpregnant women withPreeclampsiawith Normotensive pregnant women
Secondary Objective:
To determine the association ofserum High sensitive -C reactive protein levelswithseverity of adverse fetomaternaloutcomesinpregnant women with Preeclampsia.
Methods: This prospective cohort study involves 91 participants, including preeclamptic and gestational age-matched normotensive pregnant women at AIIMS Raipur. Participants were selected based on strict inclusion and exclusion criteria. Blood samples were analyzed for HS-CRP using immunoturbidimetric methods, and outcomes were correlated with adverse maternal and perinatal events. Statistical analysis was performed using SPSS with p<0.05 considered significant.
Results: Elevated HS-CRP levels were significantly higher in preeclamptic women compared to normotensive controls. Furthermore, increased HS-CRP levels strongly correlated with adverse maternal outcomes, such as severe hypertension and HELLP syndrome, and adverse perinatal outcomes, including fetal growth restriction and intrauterine death.
Conclusion: HS-CRP is a reliable prognostic biomarker for preeclampsia, correlating with disease severity and adverse outcomes. Early identification of elevated HS-CRP may guide clinical management to improve outcomes.
Keywords: Preeclampsia, HS-CRP, prognostic biomarker, inflammation, adverse outcomes, maternal health.
